ACCC COVID-19 Resource Center & Listserv
for Insights on Providing Optimal Patient Care During the Pandemic.
Providing a VOICE for Arizona's MULTIDISCIPLINARY CANCER CARE TEAMS and the PATIENTS THEY SERVE since 1991
Meetings & Education
Financial Advocacy & Patient Assistance
TACOS Advocacy Support
Patient Advocacy Organizations
State & Federal Resources
Find a Clinical Trial
TACOS Corporate Members
Become a Corporate Member
Industry News Archive
FDA Approves Atezolizumab for Metastatic NSq NSCLC
On December 6, 2018, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc.), in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of patients with metastatic non-squamous, non-small cell lung cancer (NSq NSCLC) with no EGFR or ALK genomic tumor aberrations.
Read FDA announcement
Tweets by OSSatACCC